US › Healthcare

Acurx Pharmaceuticals LLC (ACXP)

US · Healthcare · Biotechnology

$1.10-5.98%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-2.3M

EPS

$-0.53

EPS estimate

$-0.42

EPS came in at -0.53 against a street estimate of -0.42 — a miss of 26.2%.

Key statistics

Market cap

$6.1M

Forward P/E

0.0

P/B

0.72

Book value

$1.74

EPS (TTM)

$-2.67

52-week high

$7.54

52-week low

$1.07

50-day MA

$1.37

200-day MA

$2.06

Beta

-2.05

Analyst view

Analysts rate Acurx Pharmaceuticals LLC a strong buy (3 buy, 0 hold, 0 sell out of 3) with an average price target of $17.00.

Shareholding

Insiders

2.31%

Institutions

3.65%

Largest institutional holders

Fund	Stake
Vanguard Capital Management, LLC	0.56%
Geode Capital Management, LLC	0.48%
Vanguard Fiduciary Trust Co	0.29%
Jane Street Group LLC	0.28%
Prospect Financial Services Llc	0.25%
Morgan Stanley - Brokerage Accounts	0.12%
Integrated Wealth Concepts LLC	0.09%
Tower Research Capital LLC	0.05%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Acurx Pharmaceuticals LLC — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-19.